You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Cholangiocarcinoma (CCA)

Showing 1 - 25 of 416
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)

Completed
  • Primary Sclerosing Cholangitis
  • Cholangiocarcinoma
  • MR/MRCP
  • Stockholm, Sweden
    Karolinska University Hospital, Huddinge
Sep 8, 2021

Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma Trial in Frankfurt am Main (Durvalumab,

Recruiting
  • Biliary Tract Cancer (CCA)
  • +4 more
  • Frankfurt am Main, Germany
    Krankenhaus Nordwest
Jun 23, 2022

Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable Trial in Hannover (Durvalumab, Gemcitabine,

Active, not recruiting
  • Cholangiocarcinoma
  • +3 more
  • Durvalumab
  • +3 more
  • Hannover, Germany
    Medizinische Hochschule Hannover, Klinik für Gastroenterologie,
Oct 14, 2021

Precision Medicine for Combined

Recruiting
  • Liver Cancer
  • phenotyping
  • Créteil, France
    Julien Calderaro
Nov 17, 2023

Cholangiocarcinoma, Bile Duct Tumor, Biliary Tract Malignancy Trial run by the National Cancer Institute (NCI) (Tivozanib)

Recruiting
  • Cholangiocarcinoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 6, 2022

Cholangiocarcinoma Trial (Carrilizumab, Albumin-bound paclitaxel, Apatinib)

Not yet recruiting
  • Cholangiocarcinoma
  • (no location specified)
Dec 9, 2022

Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement Trial (TAS-120)

Not yet recruiting
  • Advanced Cholangiocarcinoma
  • +2 more
  • (no location specified)
Feb 3, 2023

Intrahepatic Cholangiocarcinoma Trial in Tianjin (Regorafenib and HAIC, FOLFOX)

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Sep 7, 2022

Cholangiocarcinoma Trial in Worldwide (Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemo)

Active, not recruiting
  • Cholangiocarcinoma
  • Fimaporfin and Gemcitabine
  • Gemcitabine/Cisplatin chemotherapy
  • Duarte, California
  • +49 more
Mar 4, 2022

Combined Hepatocellular Cholangiocarcinoma Trial (gemcitabine ,oxaliplatin,anlotinib,Sintilimab)

Not yet recruiting
  • Combined Hepatocellular Cholangiocarcinoma
  • gemcitabine ,oxaliplatin,anlotinib,Sintilimab
  • (no location specified)
Sep 10, 2023

Cholangiocarcinoma, Liver Fluke-Related Cholangiocarcinoma, Opisthorchiasis Trial in Nai Muang (eCHEC program)

Not yet recruiting
  • Cholangiocarcinoma
  • +2 more
  • eCHEC program
  • Nai Muang, Khon Kaen, Thailand
    Khon Kaen University
Apr 8, 2022

Cholangiocarcinoma, Liver Cancer Trial in Houston (Infigratinib, Atezolizumab, Bevacizumab)

Not yet recruiting
  • Cholangiocarcinoma
  • Liver Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements Trial in Worldwide (TAS-120, Cisplatin/Gemcitabine)

Active, not recruiting
  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Rearrangements
  • Albuquerque, New Mexico
  • +100 more
Feb 1, 2023

Common Bile Duct Tumors, Non-Neoplastic Bile Duct Disorder Trial in Worldwide (AI model classification, DSOC endoscopist

Active, not recruiting
  • Common Bile Duct Neoplasms
  • Non-Neoplastic Bile Duct Disorder
  • AI model classification
  • DSOC endoscopist experts' classification
  • New Brunswick, New Jersey
  • +5 more
Mar 30, 2022

Cholangiocarcinoma Trial in Düsseldorf (Ivosidenib Oral Tablet)

Recruiting
  • Cholangiocarcinoma
  • Ivosidenib Oral Tablet
  • Düsseldorf, Germany
    Klinik für Gastroenterologie, Hepatologie und Infektiologie Univ
May 17, 2023

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma, Determine Efficacy of Liver Transplantation After Neoadjuvant

Not yet recruiting
  • Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma
  • Determine Efficacy of Liver Transplantation After Neoadjuvant Systemic Therapy in Patients With Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma
  • Liver Transplant
  • Newark, New Jersey
  • +1 more
Nov 14, 2023

Cholangiocarcinoma Trial in Brussels, Beirut, Luxembourg (BMS-936558)

Terminated
  • Cholangiocarcinoma
  • Brussels, Belgium
  • +3 more
Feb 7, 2022

Detecting IgG4-related Sclerosing Cholangitis

Completed
  • IgG4-related Sclerosing Cholangitis
  • IgG4-related Disease
    • Rochester, Minnesota
    • +1 more
    Jan 3, 2022

    Cholangiocarcinoma Trial in Shanghai (Pemigatinib)

    Active, not recruiting
    • Cholangiocarcinoma
    • Shanghai, Shanghai, China
      Zhongshan Hospital Affiliated to Fudan University
    Oct 3, 2022

    Perihilar Cholangiocarcinoma Trial in Amsterdam (Intrahepatic biliary stent with retrieval string)

    Recruiting
    • Perihilar Cholangiocarcinoma
    • Intrahepatic biliary stent with retrieval string
    • Amsterdam, Netherlands
      Amsterdam UMC
    May 23, 2023

    l Science Network of Precision-based Immunotherapy for Primary

    Recruiting
    • Hepatocellular Carcinoma
    • +2 more
      • La Jolla, California
      • +6 more
      Jan 24, 2023

      Perihilar Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer Trial in Oslo (Liver transplant)

      Recruiting
      • Perihilar Cholangiocarcinoma
      • +2 more
      • Liver transplant
      • Oslo, Norway
        Oslo university hospital
      Aug 5, 2021

      Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors Trial in

      Active, not recruiting
      • Cholangiocarcinoma
      • +5 more
      • Gilbert, Arizona
      • +57 more
      Jan 5, 2022

      Hepatocellular Carcinoma, Cancer of Liver Trial (PXS-5505 and Atezolizumab and Bevacizumab)

      Recruiting
      • Hepatocellular Carcinoma
      • Cancer of Liver
      • PXS-5505 and Atezolizumab and Bevacizumab
      • Rochester, New York
        University of Rochester
      Nov 3, 2022